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Characterization of insulin-like growth factor hinding proteins and
regulation of IGFBP3 in human mesangial cells. IGF-I regulates renal
growth and development. Insulin-like growth factor binding proteins(IGFBPs) are synthesized by the kidney and may modulate the local
autocrine and/or paracrine actions of IGF-I. We have previously demon-
strated that mesangial cells (MC) release IGF-l and IGF-binding activity;
however, the specific IGFBPs produced by these cells and the factors
involved in their regulation are unknown. We examined MC for expres-
sion of IGFBP-1 to -6 mRNAs and proteins. RNase protection assays
using total RNA demonstrated that MC express all of the IGFBPs.
E5251]IGFJ Western ligand blot of conditioned medium demonstrated that
MC release IGFBPs of 24, 29, 32 kDa, and a doublet at 46 kDa, consistent
with IGFBP-4, -5, -2 and -3, respectively. IGFBP species of 28 and 34 kDa
were also detected. Since IGF-I and TGF-3 arc implicated in glomerular
hypertrophy and matrix expansion, we tested their effect on IGFBPs
released by MC. IGF-I (100 ng./ml), TGF-f3 (2 ng/ml) and forskolin (10-i
at) differentially regulated the abundance of IGFBPs released in the
conditioned medium in a time-dependent manner. IGF-I and TGF-beta
were potent inducers of the release of IGFBP3 protein; however, TGF-j3,
but not IGF-I, increased IGFBP3 mRNA levels. Recombinant IGFBP3
was tested for its effect on IGF-l-induced mitogenesis. IGFBP3 inhibited
IGF-I-stimulated DNA synthesis in a dose-dependent manner with a peak
effect observed at 50 nM IGFBP3. Although TGF-f3 is a potent inhibitor of
IGF-I-stimulated DNA synthesis, this effect is not mediated via IGFBPs.
Expression of IGFBP-1 to -6 by MC suggests that these proteins may
modulate IGF-I bioavailability in the glomerulus. IGF-I itself, TGF-p and
cAMP agonists may indirectly modulate the effects of IGF-I via the release
of IGFBPs by MC.
Insulin-like growth factors-I and -II (IGF-I and -II) play an
important role in kidney embryogenesis and function [1, 2].
Glomeruli and segments of the distal nephron are targets for
circulating IGFs and provide a source of local IGF-I production
[1]. The systemic administration of IGF-I has been shown to
increase renal plasma flow, glomerular filtration rate and kidney
volume in rats and humans [3, 4]. Increased circulating or locally
produced IGF-I have also been implicated in the pathogenesis of
renal hypertrophy associated with unilateral nephrectomy, diabe-
tes, hypersomatotropism, and a high protein diet [5—10]. In
chronic diabetic nephropathy, lOP-I may act in concert with
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TGF-/3 to enhance extracellular matrix deposition within the
glomerulus.
The biologic action of IGF-I/II in the kidney may be modulated
by a family of six IGFBPs, designated IGFBP-1 to -6. These
IGFBPs bind with high affinity to lOP-I and -II, but not to insulin
[11]. They serve as a reservoir and prolong the biologic half-life of
TOPs in the circulation. Depending on the IGFBP species, target
cell and culture conditions, IGPBPs may either inhibit IGF action
by forming inactive complexes with IGFs or enhance TOP action
by facilitating IGF interaction with surface receptors [12]. Certain
TGFBPs provide a storage site for IGFs in the extraeellular matrix
[13]. In addition, IGFBP-3 and -5 have intrinsic biologic activity
independent of IGFs [14, 15].
IGPBPs are abundant in the human kidney and demonstrate
distinct cellular distribution. By in situ hybridization, IGFBP-1 to
-5 mRNAs arc expressed in glomeruli; however, the precise
IGFBPs produced by the different cell types that comprise the
glomerulus have not been determined [16]. We have previously
demonstrated that human mesangial cells express lOP-I mRNA,
lOP-I receptors and release IGF-I and IGF-binding activity [17].
These cells provide a useful model for determining the spectrum
of IGFBPs released by mesangial cells, the factors that regulate
IGFBP gene expression, and the role of each IGFBP in modulat-
ing lOP action in the glomerulus. Previous studies have demon-
strated that adenylate cyclase agonists such as forskolin, and
cytokines including IGF-I and TOF-J3, regulate IOFBPs in fibro-
blasts and other cell types [18—20].
In this study, we determined the molecular identity of each
IGFBP released by human mesangial cells. The effect of IGF-I,
TOP-f3 and the cAMP agonist, forskolin, on IGFBPs released by
mesangial cells was determined. Since IGFBP3 was markedly
induced by lOP-I and TGF-3, recombinant IOFBP3 was tested
for its effect on IGF-I-induced DNA synthesis in mesangial cells.
Whether IGFBPs are involved in mediating the inhibitory effect of
TGF-13 on TOP-I-stimulated DNA synthesis was also explored.
Methods
Materials
Porskolin was obtained from Sigma Chemical Co. (St. Louis,
MO, USA). Recombinant human TGP-1 was from R&D Sys-
tems, Inc. (Minneapolis, MN, USA) and recombinant human
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IGF-I and R3-IGF-I from GroPep (Adelaide, Australia). Recom-
binant human IGFBP3 was purchased from Upstate Biotechnol-
ogy, Inc. (Lake Placid, NY, USA). Rainbow molecular mass
markers and radiolabeled IGF-I was obtained from Amersham
(Arlington Heights, IL, USA). Centricon 10 concentrators were
from Amicon (Danvers, MA, USA). RNAzol B was purchased
from Cinna Biotex (Houston, TX, USA) and the Riboprobe Kit
from Promega (Madison, WI, USA).
Antisense RNA probes. The probes for human IGFBP-2, -4, -5
and -6 were provided by Dr. Shimasaki (Whittier Institute, La
Jolla, CA, USA) [11]. Each probe was derived from a eDNA
fragment corresponding to part of the protein-coding region and
cloned into pBluescript SKI. The IGFBP2 and IGFBP4 probes
were synthesized from a StyI-EcoRV 382-bp and an EcoRI-
Hindlil 505-bp fragment, respectively. The IGFBP5 and IGFBP6
probes were synthesized from a SacII-Saci 317-bp and a PstI-PstI
267-bp fragment, respectively. IGFBP-1 and -3 probes (provided
by Dr. D. Powell, Baylor University, Waco, TX, USA) were
synthesized from a PstI-PstI 369-bp and a PstI-EcoRI 535-bp
fragment, respectively. The human 36B4 eDNA probe detects a
ubiquitously expressed ribosomal phosphoprotein and was pro-
vided by Dr. P. Chambon (INSERM, Institut de la Sante et de Ia
Recherche Medicale) [21].
Cell culture
Human mesangial cells were cultured from glomeruli isolated
by differential sieving as previously described [22]. Portions of
normal renal cortex were obtained from kidneys judged unsuit-
able for transplantation. Epithelial cells were removed by di-
gestion with collagenase. Glomerular cores were cultured in
Waymouth's medium (GIBCO, Grand Island, NY, USA) supple-
mented with 15 mi Hepes, 0.6 U/mi insulin, 2 mrvi glutamine, 0.1
m nonessential amino acids, 1 m sodium pyruvate, antibiotic/
antifungal solution, and 17% fetal calf serum (FCS). Cells were
used between passages three to ten.
RNase protection assay
To determine constitutive IGFBP-1 to -6 mRNA expression, total
RNA was isolated from confluent cultures of mesangial cells
maintained in Waymouth's medium with serum. Total RNA was
isolated using RNAzoI B method. Concentrations were deter-
mined by spectrophotometry; integrity and quantitation was con-
firmed by visualizing ethidium bromide-stained 28S and 18S
ribosomal bands on 1% agarose gels. For experiments designed to
determine the effect of forskolin, IGF-I and TGF-/3 on IGFBP3
mRNA and protein, confluent MC were washed three times with
serum-free, insulin-free (SFIF) medium and incubated 24 hours in
the same medium. Fresh SFIF medium with or without forskolin,
IGF-I, or TGF-J3 was added. Cell-free supernatants were col-
lected at 8 and 24 hours and used for Western ligand blot analysis.
Cells were also harvested for total RNA at these time points and
at 72 hours. RNase protection assay was carried out as we have
previously described [23]. 32P-labeled single-stranded RNA
probes were synthesized in an antisense orientation using SP6, T7
or T3 RNA polymerase. After hybridization, samples were di-
gested sequentially with RNases A and Ti and proteinase K. The
products were analyzed by electrophoresis through a 7 M urea/6%
acrylamide gel, followed by autoradiography.
Western ligand blot
Samples were concentrated 40-fold by ultrafiltration in Centri-
con 10 microconcentrators (10 kDa molecular wt cutoff). Ligand
blotting with [1251]IGF-I was performed by the method of Hos-
senlopp et a! [24] as previously described [25]. Briefly, samples
were electrophoresed through a 10% SDS-polyacryiamide gel.
Separated proteins were electroblotted onto nitrocellulose filters
and then incubated with [1251]IGF-I overnight at 4°C and visual-
ized by autoradiography.
[3H/thymidine ([3H]TdR) assay
Confluent cells were made quiescent by incubation in SFIF
medium for 72 hours. They were then washed once with SFIF
medium and incubated in same medium with IGF-I (200 ng/ml)
and R3-IGF-I (200 ng/ml) alone and in combination with TGF-13
(2 ng/ml). In some experiments, IGF-I and R3-IGF-I were incu-
bated in the presence and absence of various concentrations of
IGFBP3. Cells were pulsed with [3H]TdR (1 iCi/ml) for four
hours prior to harvesting at 28 hours. The amount of [3H]TdR
incorporated into TCA-precipitable material was determined by
liquid scintillation counting.
Statistical analysis
Analysis of the difference of the means among treatment groups
was determined utilizing Tukey's Studentized Range Test. The
results in Figure 4 represent the mean of at least three separate
experiments SEM.
Results
IGFBP gene expression in human mesangial cells
IGFBP mRNAs are expressed in the glomerulus. We examined
the specific IGFBP mRNAs expressed by mesangial cells. Total
RNA isolated from mesangial cells was hybridized with human
IGFBP-i to -6 antisense RNA probes and analyzed using a
sensitive RNase protection assay. Figure 1 demonstrates that
mesangial cells constitutively express abundant levels of IGFBP-2
to -6 mRNAs, and to a lesser extent IGFBP1 mRNA. For each
IGFBP analyzed, human breast carcinoma cell lines, MDA-MB
231 or MCF-7, were used as controls since they are known to
express certain IGFBP mRNAs [26]. Autoradiograms show the
expected protected fragment in both the control and mesangial
cell total RNAs: 369-bp for IGFBP1; 325-bp for IGFBP2; 535-bp
for IGFBP3; 505-bp for IGFBP4; 317-bp for IGFBP5 and 267-bp
for IGFBP6. These fragments are specific and not observed in the
tRNA lane.
Characterization of IGFBPs in mesangial cell conditioned medium
To determine if IGFBP mRNA expression is associated with
the release of the corresponding IGFBPs, conditioned medium
from mesangial cells was analyzed by ligand blotting with
['251]IGF-I. In Figure 2, the first lane shows conditioned medium
obtained from ovarian carcinoma cells (OVCAR-3) that contain
IGFBPs of 24, 29 (not visualized), 32 kDa and a doublet at 46 kDa
that correlate with IGFBP-4, -5, -2 and -3, respectively, as we have
previously shown [25]. The constitutive release of IGFBPs from
confluent mesangial cell cultures incubated under unstimulated,
serum-free, insulin-free conditions is shown in lanes labeled
control (8 and 24 hr). At eight hours, the 24 kDa species
predominates with less abundant species of 29, 32, and 46 kDa. At
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Fig. 1. RNase protection assays for IGFBP mRNA expression by mesangial cells. 32P-labeled LGFBP-1 to -6 antisense RNA probes were hybridized with
total RNA (30 sg) isolated from mesangial cells. Total RNA from human breast cancer cell lines (MDA-MB-23 1 or MCF-7) were used as controls.
Autoradiograms show the predicted protected fragment in both controls and mesangial cells. Probes hybridized with tRNA were completely digested
by RNases. Last lane of each panel shows undigested IGFBP probes. The migration of 32P-labeled DNA markers is shown to the left (in basepairs).
24 hours, there is a predominance of the 46 kDa doublet and the
32 kD IGFBP. Less abundant IGFBP species are seen at 24 kDa
and at approximately 26 and 34 kDa; the 29 kDa IGFBP present
at eight hours is no longer observed at 24 hours. The precise
identity of the 26 and 34 kDa species is unknown, but the 26 kDa
band may represent either a glycosylated form of IGFBP4 or
IGFBP1; the 34 kDa band may be a glycosylated IGFBP. The 46
kDa doublet present in the medium was more abundant at 48
hours compared to 24 hours (data not shown). These findings
indicate that the relative abundance of IGFBPs in mesangial cell
conditioned medium varies in a time-dependent fashion. Release
of IGFBP-2, -3, -4, -5 and possibly -1 and -6 by mesangial cells
correlates with expression of these IGFBP mRNAs. IGFBP6 may
not be detected by [1251]IGF-I ligand blot since IGFBP6 protein
has a higher affinity for IGF-II than IGF-I.
Regulation of IGFBPs in mesangial cell conditioned medium by
forskolin, JGF-I and TGF-/3
cAMP agonists and various cytokines have been shown to
regulate IGFBP proteins in other systems. We performed time
course experiments to determine the effect of forskolin, IGF-I and
TGF-13 on IGFBPs released by mesangial cells. Figure 2 shows
that IGFBPs are differentially regulated by these agents. Forsko-
lin induced 24 kDa IGFBP4 and, to a lesser extent, 29 kDa
IGFBP5 at eight hours compared to control. At 24 hours, IGFBP4
levels were similar in control and forskolin-treated samples, and a
decrease in 32 kDa IGFBP2 was observed. IGF-I primarily
induced IGFBP-2 and -5 and slightly increased 46 kDa IGFBP3
doublet at eight hours. By 24 hours, accumulation of IGFBP-2
and -3 markedly increased in response to IGF-I, an effect also
observed on the 26 kDa species. TGF-f3 primarily induced
IGFBP-4 and -2 and slightly increased IGFBP3 at eight hours.
Similar to IGF-I, TGF-f3 markedly increased the accumulation of
IGFBP-2 and -3 at 24 hours. This effect persisted in cultures
exposed to TGF-J3 for 48 hours (data not shown).
Regulation of JGFBP3 mRNA by forskolin, IGF-J and TGF-13
Since IGFBP3 showed the strongest response to cytokines,
experiments were carried out to determine if IGFBP3 is regulated
at the level of mRNA abundance (Fig. 3). RNA was isolated from
the same experiment described in Figure 2 and from an additional
48 hours time point. In unstimulated cells, IGFBP3 mRNA
increased in a time-dependent manner (control 8, 24 and 48 hr),
similar to the protein levels observed on the ligand blot. Forskolin
increased IGFBP3 mRNA expression at eight hours with a peak
effect observed at 24 hours, and a decline to basal levels by 48
hours. Although a corresponding increase in IGFBP3 protein was
not observed in this experiment, other experiments showed induc-
tion of IGFBP3 protein by forskolin. While IGF-l appeared to
slightly decrease IGFBP3 mRNA at each time point tested,
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Fig. 2. Time course for the effect of forskolin, IGF-I and TGF-P on IGFBPs by Western ligand blot analysis. Confluent cells were made quiescent by placing
them in SFIF medium for 24 hours. Forskolin (10 M), IGF-l (100 ng/ml) or TGF-/3 (2 ng/ml) were then added and cells incubated for thc indicated
time points. Samples were electrophoresed through a nonreducing 10% SDS-polyacrylamide gel and transferred to nitrocellulose. After incubation with
[1251j1GF-l, filter-immobilized IGFBPs were visualized by autoradiography after two days exposure. The migration positions of molecular size markers
(in kDa) are indicated on the left.
TGF-/3 was a potent inducer of IGFBP3 mRNA at 24 and 48
hours compared to control. Thus, the effect of TGF-/3, but not
IGF-1, on IGFBP3 mRNA expression correlated with IGFBP3
protein abundance as measured by ligand blotting. Control 36B4
mRNA did not vary in response to the test agents, demonstrating
that the response in IGFBP3 mRNA does not simply reflect a
generalized nonspecific change in total RNA expression (Fig. 3,
lower panel). Similar results were observed in two separate
experiments.
Effect of recombinant JGFBP3 on JGF-J-induced DNA synthesis
in mesangial cells
Since IGFBP3 may modulate IGF-I action, the effect of recom-
binant human IGFBP3 on IGF-I-stimulated DNA synthesis in
mesangial cells was determined. Figure 4 shows that IGFBP3
inhibited IGF-I-induced mitogenesis in a dose-dependent manner
with approximately 35% inhibition at 25 nM and 50% inhibition at
50 mM IGFBP3. Addition of 50 nM IGFBP3, a concentration
twofold higher than IGF-I, completely abrogated the mitogenic
effect of IGF-I. Although there was some variation in IGF-
induced DNA synthesis from 1.5- to 2.5-fold compared to control,
the addition of 25 and 50 tiM IGFBP3 consistently inhibited the
effect of IGF-I. To determine if the effect of IGFBP3 was specific
for IGF-I-stimulated DNA synthesis, and required the interaction
between the binding protein and ligand, we tested the effect of
IGFBP3 on R3-IGF-I-induced DNA synthesis. R3-IGF-1 is an
analogue of IGF-l that retains affinity for IGF-1 receptors but fails
to complex with IGFBPs. As shown in Figure 4, 50 nM IGFBP3
did not influence DNA synthesis induced by R3-IGF-1. Incubation
of cells with IGFBP3 alone showed no significant effect on basal
DNA synthesis, suggesting that any endogenous production of
IGFs by cells, under these experimental conditions, did not result
in autocrine regulation. Perhaps released IGF-I is immediately
sequestered by endogenously released IGFBPs.
Effect of TGF-13 on IGF-I and R3-IGF-I-induced DNA synthesis
in mesangial cells
We and others have previously demonstrated that TGF-p
inhibits DNA synthesis in mesangial cells and blocks the mito-
genic effect of certain cytokines {27. The marked induction of
IGFBP3 protein by TGF-13 suggests that TGF-f3 may inhibit the
mitogenic effect of IGF-I via the release of IGFBP3. Figure 5
shows that IGF-I and R3-IGF-I stimulated DNA synthesis in
mesangial cells compared to control. TGF-/3 alone inhibited basal
DNA synthesis. When co-incubated with TGF-13, the mitogenic
effects of both IGF-I and R3-IGF-I were markedly inhibited.
These findings suggest that the inhibitory effect of TGF-J3 is not
mediated via an IGF-binding protein.
Discussion
The present study demonstrates that human mesangial cells in
culture constitutively express IGFBP-1 to -6 mRNAs and release
IGFBPs. Recent work has shown that human glomeruli express
IGFBP-1 to -5 mRNAs. IGFBP1 mRNA was localized to parietal
epithelial cells along the glomerular capsule and IGFBP2 mRNA
was present in glomerular cells with a distribution pattern of
epithelial cells {16. However, the precise molecular identities of
each IGFBP expressed by the individual cell types that comprise
the glomerulus are unknown. By RNase protection assay, human
mesangial cells expressed abundant IGFBP-2 to -6 mRNAs and,
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Fig. 3. Time course for the effect of forskolin, IGF-I and TGF-13 on IGFBP-3 mRNA expression. RNase protection assay of total RNA (30 xg/1ane) isolated
from the same experiment described in Figure 2. 32P-labeled human antisense IGFBP-3 and 36B4 RNA probes were simultaneously hybridized with
mesangial cell total RNA. Autoradiogram shows the expected 535-hp protected fragment for IGFBP-3.
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Fig. 4. Inhibitoiy effect of IGFBP-3 on IGF-I-induced DNA synthesis. Cells
were plated in 24-well dishes at 3 to 5 x io cells/well in Waymouth's
medium with serum. At confluence, cells were made quiescent by incuba-
tion in SFIF medium for 72 hours and then placed in the same medium
with or without IGF-I and R3-IGF-I (200 ng/ml) in the presence of
increasing concentrations of IGFBP-3. Control wells were incubated with
SFIF medium alone. Cells were pulsed with [3H]TdR (1 rCi/ml) for four
hours prior to harvesting at 28 hours. Data represent the mean SEM of
three to four separate experiments each performed in triplicate wells.
Symbols are: (LI) control; (U) IGF-I; () R3-IGF-I. Asterisks indicate
significant difference from cells treated with IGF-I in the absence of
IGFBP-3 or cells treated with R3-IGF-l in the presence and absence of
IGFBP-3 (*P < 0.01; < 0.001).
to a lesser extent, IGFBP1 mRNA. IGFBP gene expression
correlated with the release of the corresponding IGFBP into
conditioned medium, although the release of IGFBP-1 and -6 will
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Fig. 5. Inhibitoiy ejfrct of TGF-/3 on IGF-I and R-IGF-I-induced DNA
synthesis. Confluent quiescent mesangial cells were incubated with IGF-l
and R3-IGF-I (200 ng/ml) in the presence and absence of TGF-/3 (2
nglml). Cells were pulsed and harvested as described in Figure 4. Data
represent the mean SEM of triplicate determinations from one of two
similar experiments. Asterisks indicate significant difference from cells
treated with IGF-I (*P < 0.001) or R3-IGF-l (**P < 0.001) alone.
require further confirmation by immunoblot analysis. These find-
ings also demonstrate that IGFBP6 is expressed by glomerular
cells, in contrast to previous studies that have failed to detect
IGFBP6 mRNA in the human kidney [161.
The expression of multiple IGFBPs by mesangial cells suggests
that the ratio of one IGFBP to another may be an important
factor in determining autocrine and paracrine actions of IGF-I in
S. .5*0*0..
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the glomerulus [28]. The overall net effect of IGF-I would depend
upon the relative abundance of each IGFBP that may interact in
either a synergistic or opposing manner to modulate IGF action.
IGFBP-1, -2, -3 and -5 may either enhance or inhibit IGF-
mediated effects under varying incubation conditions, while
IGFBP4 demonstrates only inhibitory activity. For IGFBPI, the
biologic effect depends on the prevalence of phosphorylated and
nonphosphorylated forms [29].
Although the effect of these IGFBPs in modulating IGF actions
in renal disease are unknown, recent studies suggest that they play
an important role. Induction of diabetes in rats by streptozotocin
causes rapid renal hypertrophy that is preceded by a rise in kidney
tissue IGF-I levels 24 to 48 hours after the onset of diabetes [7].
During this time, there is a coordinant increase in IGFBP3 and a
30 kDa IGFBP species in whole kidney extracts and an increase in
IGFBP1 mRNA expression [30, 31]. By in situ hybridization, there
is a predominant increase in IGFBP-l and -5 mRNA levels in the
cortex and medulla, respectively [32]. The observation that treat-
ment of rats with insulin, a potent inhibitor of IGFBP1, prevents
the induction of IGFBPs and inhibits renal growth, suggests that
IGFBP1 may be important for the initiation of renal hypertrophy
[33, 34].
The relative abundance of IGFBPs in the kidney is dependent,
in part, on the regulation of each IGFBP by growth factors and
hormones. In other systems, IGFBPs are regulated by agents that
increase cAMP, IGF-I and TGF-/3, factors also implicated in the
development of renal pathology [35—38]. Mechanisms that govern
the synthesis and secretion of each IGFBP are complex. IGFBP
levels in mesangial cell conditioned medium may be influenced by
several factors including differential transcription rate, post-trans-
lational modifications, alterations in membrane-associated frac-
tions of certain IGFBPs and specific IGFBP proteases [39]. Under
basal conditions, the relative ratio of IGFBPs in mesangial
conditioned medium changed with time. IGFBP-2 and -3 protein
levels increased while IGFBP-4 and -5 decreased between 8 to 24
hours. In the case of IGFBP-3, increased protein levels correlated
with a time-dependent increase in IGFBP-3 mRNA abundance.
In mesangial conditioned medium forskolin, IGF-I and TGF-13
induced distinct patterns of IGFBPs, with a prominent increase in
IGFBP-3. Forskolin, a direct activator of adenylate cyclase, was
used as a tool to determine the effect of increased cAMP levels on
IGFBPs. RNase protection assay demonstrated that forskolin
increased IGFBP-3 mRNA levels. Previous studies have shown
that IGFBP-3 is regulated in a tissue- and cell type-specific
manner [40]. In MDBK epithelial cells and in fibroblasts, forskolin
also increased IGFBP-3 mRNA and protein levels, whereas in
osteoblasts, forskolin inhibited IGFBP-3 [18, 28, 41].
IGF-I and TGF-f3 were potent inducers of IGFBP-3 protein
release in mesangial cells; however, TGF-p, but not IGF-I,
markedly increased IGFBP-3 mRNA levels. These findings sug-
gest that IGFBP-3 is regulated by distinct mechanisms: forskolin
and TGF-13 act by increasing de novo synthesis of IGFBP-3, while
IGF-I acts by post-transcriptional mechanism(s). Similar results
have been obtained in human fibroblasts [19]. In these cells, the
effect of TGF-p on IGFBP-3 was at the level of mRNA abun-
dance, while IGF-I altered the amount of surface bound
IGFBP-3. IGFBPs synthesized by fibroblasts may remain cell
surface-associated. IGF-I analogues with reduced affinity for
IGF-I receptors, but near-normal affinity for IGFBP-3, decreased
surface bound IGFBP-3 and increased IGFBP-3 in the condi-
tioned medium. IGFBP-3 was regulated in a similar manner by
heparin, an agent that releases proteins attached to cell surface
proteoglycans. These findings suggest that IGF-I regulates
IGFBP-3 post-transcriptionally by increasing the release of
IGFBP-3 from the cell surface or matrix proteoglycans. Perhaps
in mesangial cells, IGF-I also releases cell-surface associated
IGFBP-3, although this remains to be determined. Alternatively,
IGF-I may influence IGFBP levels by other post-transcriptional
mechanisms. In certain systems, IGF-I induces certain IGFBPs by
directly binding to them, thereby protecting against proteolysis
[28]. It is also possible that IGF-I, like other agents, increases
IGFBPs by inducing a specific protease inhibitor [42]. Whether
one or a combination of these mechanisms play a role in
IGF-I-mediated increase of IGFBP-3 protein released by mesan-
gial cells requires further study.
Release of endogenous IGFBP-3 may influence the mitogenic
effect of IGF-I on mesangial cells. In fibroblast cultures, simulta-
neous addition of IGFBP-3 with IGF-I inhibits the mitogenic
action, while preincubation of the cells with IGFBP-3 prior to the
addition of IGF-I potentiates IGF action [12]. Studies suggest that
inhibition of IGF action is through interaction with soluble
IGFBP-3, while potentiation occurs via cell surface-associated
IGFBP-3 [43]. Co-incubation of IGFBP-3 with IGF-I or R3-IGF-I
completely abrogated IGF-I, but not R3-IGF-I-induced mitogen-
esis in confluent mesangial cultures. These findings suggest that
inhibition of IGF-I bioactivity is due to IGFBP-3 sequestering
IGF-I, thereby preventing the interaction of IGF-I with its
receptor. This is also supported by the observation that IGFBP-3
alone had no effect on mesangial cell DNA synthesis. In other
systems, however, IGFBP-3 has been shown to have a direct
inhibitory action on cell growth in the absence of IGF-I or -II [14].
Induction of IGFBP-3 by TGF-f3 suggests that IGFBP-3 may
mediate the inhibitory effect of TGF-f3 on IGF-I-induced DNA
synthesis. Inhibition of both IGF-I and R3-IGF-I-induced DNA
synthesis by TGF-13, however, indicates that the inhibitory effect
of TGF-/3 is not mediated via an IGFBP. These results are in
contrast to those reported by Yateman et al [20], where TGF-13
blocked the mitogenic response of fibroblasts to IGF-I via release
of an endogenous IGFBP, probably IGFBP-3. Perhaps other
factors are involved in mediating the effect of TGF-f3 in mesangial
cells such as down-regulation of IGF-I receptors or alteration of
IGF-I signaling pathways by TGF-13 [44].
The physiological significance of IGFBPs in renal disease
remains to be elucidated. In diabetic nephropathy, one may
speculate that IGF-I and insulin regulate IGFBPs. The transient
increase in IGFBP-1, IGFBP-3 and perhaps other IGFBPs and
the relative ratio of stimulatoiy versus inhibitory IGFBPs in the
glomerular microenvironment may play a key role in determining
IGF action. Both IGF-I and TGF-J3 may act synergistically to
enhance matrix formation, as well as modulate IGFBP levels that,
in turn, influence IGF-I-mediated effects. Further understanding
of the mechanisms involved in regulating IGFBP expression and
their interaction with IGFs in the glomerulus is required to
understand the complex role of this system in glomerular pathol-
ogy.
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